In this study, PIK3CA mutation was screened from 810 lung adenocarcinoma patients and its frequency, treatment and prognosis was evaluated, in order to enrich the understanding of PIK3CA as a driver gene in NSCLC treatment. This evidence concerns the gene PIK3CA and lung adenocarcinoma.